NEW YORK (GenomeWeb) – Rheonix today said it received a Small Business Innovation Research Phase I Fast-Track grant to complete the development of its fully automated self-confirming assay for the simultaneous detection of HIV/AIDS antibodies and viral RNA in a single specimen.

The grant from the National Institutes of Health is for six months and $189,646. Ithaca, NY-based Rheonix said it anticipates being awarded a follow-on 18-month, $1.5 million Phase II award.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.